10:59 AM EST, 01/10/2025 (MT Newswires) -- Absci ( ABSI ) and Owkin said Friday that they formed a partnership to develop therapeutic candidates addressing novel targets in immuno-oncology and other indications such as inflammation.

The partnership will use Owkin's predictive AI models to optimize target selection and validate therapeutic hypotheses, while Absci's ( ABSI ) generative AI Drug Creation platform will design therapeutic candidates against the selected novel targets, according to a joint statement.

Financial terms were not disclosed.

Shares of Absci ( ABSI ) were down more than 9% in recent trading.

Price: 2.92, Change: -0.30, Percent Change: -9.32